These findings indicate that Aβo exposure in an in vitro model of AD leads to synaptogenesis and dysregulation in de novo protein synthesis and they identify eFT508 as a compound that can counteract some of these Aβo-induced dysfunctions. This evidence concerns the gene ABO and Alzheimer disease.